Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 14Neoplasms 8Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Colonic Neoplasms 2Brain Neoplasms 2Thyroid Neoplasms 1Recurrence Free Survival 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Lung Neoplasms 1Histiocytosis 1Glioma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Dihydropyrimidine Dehydrogenase Deficiency 1Advanced Solid Tumors 1

Interventions

Gemcitabine 3Radiotherapy, Intensity-Modulated 2Albumin-Bound Paclitaxel 2Taxes 1S 1 (combination) 1Radiotherapy 1Panitumumab 1Optical Imaging 1Irinotecan 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Pancreatic Adenocarcinoma × Panitumumab × Clear all
NCT03384238 2026-03-17

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Stanford University

Phase 1/2 Recruiting
27 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡